Chemotherapy combined with pembrolizumab, an immune checkpoint inhibitor that inhibits programmed cell death protein 1 (PD-1), is an efficacious option for first-line treatment of advanced NSCLC lacking targetable mutations [3, 4]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.